

## **Third Party Observations (TPOs) filed between January and December 2021**

Note:

TPO No. refers to publisher's internal reference number.

Appl. No. provides information on the International Application No. and the Publication Number.

National phase reflects information provided on WIPO's PATENTSCOPE database as at that date of preparing this document (22/12/2022). However, this data is dynamic and may not provide accurate information on the actual status of the patent application.

TPO No.	108			
Appl. No.	WO2020056145			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020056145">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020056145</a>			
Applicants	THE ROCKEFELLER UNIVERSITY			
Priority Date	62/731,356 14.09.2018 US			
Details	HIV biologic: Applicant Rockefeller University., filed an application for broad and potent antibodies against HIV and specifically to anti- HIV antibody 10-1074 variants, either alone or in combination with other therapeutic agents, including 3BNC117, and the use thereof. TPO was filed in which 5 prior art documents were used in 4 notes for challenging novelty and/or inventive step.			
Date of Filing of TPO	14/01/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	09.03.2021	<u>2019338454</u>	
	Canada	09.03.2021	<u>3112486</u>	Published 19.03.2020
	United States of America	11.03.2021	17275310	Published 21.04.2022
	Japan	12.03.2021	2021513989	
	European Patent Office	14.04.2021	<u>2019859927</u>	Published 21.07.2021
	Republic of Korea	14.04.2021	<u>1020217011145</u>	Published 26.05.2021
	China	11.05.2021	201980074145.7	Published 17.08.2021

TPO No.	109			
Appl. No.	WO2020053811			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020053811">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020053811</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/731,196 14.09.2018 US 62/733,259 19.09.2018 US			
Details	HIV: Applicant ViiV Healthcare UK Ltd., filed an application for capsid assembly HIV inhibitors, pharmaceutical compositions, and methods for using these compounds for the treatment of HIV, with other anti-HIV drugs. TPO was filed in which 4 prior art documents were used in 3 notes to challenge inventive step, and a note to challenge novelty.			
Date of Filing of TPO	14/01/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	01.03.2021	17272377	Published 24.03.2022
	Japan	12.03.2021	2021514019	
	European Patent Office	14.04.2021	<u>2019787072</u>	Published 21.07.2021

TPO No.	110			
Appl. No.	WO2020061200			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020061200">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020061200</a>			
Applicants	IONIS PHARMACEUTICALS, INC.			
Priority Date	62/733,152 19.09.2018 US			
Details	HCV: Ionis Pharmaceuticals Co. Ltd., filed an application claiming PNPLA3 inhibition using modified oligonucleotide to treat HCV/liver disease. TPO was filed in which 5 prior art documents were used in 2 notes to challenge novelty, and inventive step.			
Date of Filing of TPO	19/01/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	05.03.2021	<u>3112036</u>	Published 26.03.2020
	United Arab Emirates	10.03.2021	P6000345/2021	
	Dominican Republic	10.03.2021	DOP2021000044	Published 16.05.2021
	Thailand	10.03.2021	2101001376	
	Philippines	12.03.2021	12021550558	
	Israel	14.03.2021	<u>281492</u>	
	China	15.03.2021	201980060349.5	Published 22.06.2021
	Peru	15.03.2021	000329-2021	Published 04.06.2021
	Nicaragua	16.03.2021	2021-000018 I	Published 22.06.2021
	Singapore	16.03.2021	11202102636U	
	Japan	17.03.2021	2021514998	
	Mexico	17.03.2021	MX/a/2021/003170	Published 17.06.2021
	Brazil	23.03.2021	112021004859	
	Eurasian Patent Organization	06.04.2021	<u>202190708</u>	
	Australia	13.04.2021	<u>2019345031</u>	
	New Zealand	13.04.2021	774843	Published 30.04.2021
	Costa Rica	14.04.2021	CR2021-000180	Published 10.06.2021
	Ecuador	14.04.2021	2021-26021	
	Republic of Korea	15.04.2021	<u>1020217011204</u>	Published 01.06.2021
European Patent Office	19.04.2021	<u>2019861898</u>	Published 28.07.2021	

	Ukraine	19.04.2021	<u>a202101738</u>	Published 02.06.2021
--	---------	------------	-------------------	-------------------------

TPO No.	111			
Appl. No.	WO2020058844			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020058844">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020058844</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/733,692 20.09.2018 US			
Details	HIV: Applicant, Viiv Healthcare Ltd., filed an application claiming capsid inhibitors for treatment of HIV, administered with other anti-HIV drugs. TPO was filed in which 4 prior art documents were used in 2 notes to challenge novelty, and inventive step.			
Date of Filing of TPO	20/01/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	05.03.2021	17273748	Published 21.10.2021
	Japan	19.03.2021	2021515492	
	European Patent Office	20.04.2021	<u>2019773190</u>	Published 28.07.2021

TPO No.	112			
Appl. No.	WO2020069125			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020069125">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020069125</a>			
Applicants	DANA-FARBER CANCER INSTITUTE, INC PRESIDENT AND FELLOWS OF HARVARD COLLEGE			
Priority Date	62/738,326 28.09.2018 US			
Details	HCV: Dana Farber Cancer Institute, filed an application claiming HCV NS3/4A protease degradation using telaprevir linked to ubiquitin ligand for treatment of HCV. TPO was filed in which 4 prior art documents were used in 2 notes to challenge novelty, and/ or inventive step.			
Date of Filing of TPO	28/01/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	25.03.2021	17280075	Published 04.11.2021

TPO No.	113			
Appl. No.	WO2020072931			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020072931">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020072931</a>			
Applicants	OCTAGON THERAPEUTICS INC			
Priority Date	62/741,100 04.10.2018 US 62/809,953 25.02.2019 US 62/811,320 27.02.2019 US			
Details	TB: Applicant Octagon Therapeutics Inc., filed an application for nucleoside analogues as IMPDH inhibitors for treating infectious diseases, like TB. TPO was filed in which 5 prior art documents were used in 4 notes for challenging novelty and/or inventive step.			
Date of Filing of TPO	04/02/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	02.04.2021	17282526	Published 18.11.2021
	European Patent Office	04.05.2021	<u>2019868552</u>	Published 11.08.2021

TPO No.	114			
Appl. No.	WO2020073942			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020073942">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020073942</a>			
Applicants	SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD JIANGSU HENGRUI MEDICINE CO., LTD.			
Priority Date	201811182530.7 11.10.2018 CN			
Details	HIV, HCV: Applicant Jiangsu Hengrui Medicine Co., filed an application for prodrug compounds of TLR7 agonists for treating viral infections like HIV, HCV. TPO was filed in which 3 prior art documents were used in 2 notes to challenge novelty and/or inventive step.			
Date of Filing of TPO	11/02/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	China	26.01.2021	201980050583.X	Published 16.03.2021

TPO No.	115			
Appl. No.	WO2020081143			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020081143">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020081143</a>			
Applicants	VIRGINIA COMMONWEALTH UNIVERSITY			
Priority Date	62/747,739 19.10.2018 US			
Details	HIV: Virginia Commonwealth University, filed an application claiming compounds of HIV integrase inhibitors. TPO was filed in which 4 prior art documents were used in 2 notes to challenge inventive step.			
Date of Filing of TPO	18/02/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	European Patent Office	19.05.2021	<u>2019873886</u>	Published 25.08.2021 Withdrawn 02.11.2021
	United States of America		17286177	Published 09.12.2021

TPO No.	116			
Appl. No.	WO2020086446			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020086446">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020086446</a>			
Applicants	INTERNATIONAL AIDS VACCINE INITIATIVE			
Priority Date	62/748,610 22.10.2018 US			
Details	HIV biologic: Applicant, IAVI, filed an application claiming anti-HIV Env antibodies, specifically the PCIN63 – a VRC01 class of antibodies. TPO was filed in which 9 prior art documents were used in 4 notes to challenge inventive step.			
Date of Filing of TPO	22/02/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	21.04.2021	17287188	Published 18.11.2021
	European Patent Office	25.05.2021	<u>2019875194</u>	Published 01.09.2021

TPO No.	117			
Appl. No.	WO2020083856			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020083856">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020083856</a>			
Applicants	MERCK PATENT GMBH			
Priority Date	18306390.8 25.10.2018 EP			
Details	HCV: Merck Patent GMBH, filed an application claiming compounds as A2A and A2B adenosine receptor antagonist for treating viral and bacterial infections like HIV, HCV, and TB. TPO was filed in which 5 prior art documents were used in 3 notes to challenge inventive step.			
Date of Filing of TPO	25/02/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Mexico	24.03.2021	MX/a/2021/003508	Published 17.06.2021
	Israel	21.04.2021	<u>282527</u>	
	Singapore	21.04.2021	11202104081X	
	Canada	23.04.2021	<u>3117512</u>	Published 30.04.2020
	China	23.04.2021	201980070446.2	Published 04.06.2021
	United States of America	23.04.2021	17288164	Published 25.11.2021
	Japan	26.04.2021	2021522946	
	Brazil	04.05.2021	112021007727	
	Australia	17.05.2021	<u>2019363657</u>	
	New Zealand	21.05.2021	773722	Published 28.05.2021
	Republic of Korea	24.05.2021	<u>1020217015638</u>	Published 06.07.2021
	European Patent Office	25.05.2021	<u>2019786996</u>	Published 01.09.2021
	Russian Federation	25.05.2021	2021113838	Published 25.11.2022

TPO No.	118			
Appl. No.	WO2020083878			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020083878">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020083878</a>			
Applicants	MERCK PATENT GMBH			
Priority Date	18306389.0 25.10.2018 EP			
Details	HCV: Merck Patent GMBH, filed an application claiming compounds as A2A and A2B adenosine receptor antagonist for treating viral and bacterial infections like HIV, HCV, and TB. TPO was filed in which 5 prior art documents were used in 3 notes to challenge inventive step.			
Date of Filing of TPO	25/02/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	02.03.2021	<u>2019363662</u>	
	Mexico	05.04.2021	MX/a/2021/003901	Published 13.07.2021
	Israel	21.04.2021	<u>282526</u>	
	Singapore	21.04.2021	11202104078P	
	Canada	23.04.2021	<u>3117510</u>	Published 30.04.2020
	China	23.04.2021	201980070411.9	Published 28.05.2021
	United States of America	23.04.2021	17288077	Published 09.12.2021
	Japan	26.04.2021	2021523077	
	Brazil	27.04.2021	112021007435	
	Republic of Korea	18.05.2021	<u>1020217015092</u>	Published 06.07.2021
	New Zealand	24.05.2021	773419	Published 28.05.2021
	European Patent Office	25.05.2021	<u>2019789689</u>	Published 01.09.2021
	Russian Federation	25.05.2021	2021113839	Published 25.11.2022

TPO No.	119			
Appl. No.	WO2020089778			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020089778">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020089778</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/751,733 29.10.2018 US			
Details	HIV: Applicant Viiv Healthcare., filed an application claiming capsid inhibitors for treatment of HIV. Combination treatment with other anti-HIV drugs was also claimed. TPO was filed using 3 prior art documents in 3 notes, challenging novelty and/or inventive step.			
Date of Filing of TPO	01/03/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	15.04.2021	17285680	Published 30.12.2021
	Japan	27.04.2021	2021523159	
	European Patent Office	31.05.2021	<u>2019797382</u>	Published 08.09.2021

TPO No.	120			
Appl. No.	WO2020095176			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020095176">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020095176</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/755,627 05.11.2018 US			
Details	HIV: Applicant Viiv Health Care., filed another similar application for capsid inhibitors for HIV treatment. TPO was filed in which 4 prior art documents were used in 3 notes for challenging novelty and/or inventive step.			
Date of Filing of TPO	05/03/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	23.04.2021	17288085	Published 09.12.2021
	Japan	30.04.2021	2021523753	
	European Patent Office	07.06.2021	<u>2019801117</u>	Published 15.09.2021

TPO No.	121			
Appl. No.	WO2020095177			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020095177">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020095177</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/755,620 05.11.2018 US			
Details	HIV: Applicant Viiv Healthcare, filed one more application for capsid inhibitors for HIV treatment. TPO was filed in which 5 prior art documents were used in 3 notes to challenge novelty and/or inventive step.			
Date of Filing of TPO	05/03/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	22.04.2021	17287736	Published 23.12.2021
	Japan	30.04.2021	2021523757	
	European Patent Office	07.06.2021	<u>2019802273</u>	Published 15.09.2021

TPO No.	122			
Appl. No.	WO2020106713			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020106713">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020106713</a>			
Applicants	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.			
Priority Date	62/770,541 21.11.2018 US			
Details	HIV: Biologic: Applicant Beth Israel Deconess Medical Centre, filed an application claiming PGDM1400 antibody variants for treatment of HIV. TPO was filed in which 7 prior art documents were used in 5 notes to challenge inventive step, and/or novelty.			
Date of Filing of TPO	19/03/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	20.05.2021	17295798	Published 27.01.2022
	European Patent Office	21.06.2021	<u>2019886693</u>	Published 29.09.2021

TPO No.	123			
Appl. No.	WO2020112931			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020112931">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020112931</a>			
Applicants	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA			
Priority Date	62/772,852 29.11.2018 US			
Details	HIV: Applicant, University of Nebraska, filed an application claiming prodrugs and nano formulations of HIV integrase inhibitors, like bictegravir, dolutegravir, cabotegravir, etc. TPO was filed in which 7 prior art documents were used in 4 notes to challenge inventive step.			
Date of Filing of TPO	29/03/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	27.05.2021	17309435	Published 09.06.2022
	European Patent Office	29.06.2021	<u>2019891191</u>	Published 06.10.2021
	China	28.07.2021	201980090637.5	Published 10.09.2021

TPO No.	124			
Appl. No.	WO2020128675			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020128675">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020128675</a>			
Applicants	SVENOX PHARMACEUTICALS LLC			
Priority Date	PV 2018-664 30.11.2018 CZ			
Details	TB: Svenox Pharmaceuticals LLC, filed an application claiming derivatives of oxadiazole for treatment of TB. TPO was filed in which 2 prior art documents were used in 2 notes to challenge novelty, and/or inventive step.			
Date of Filing of TPO	30/03/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Eurasian Patent Organization	30.04.2021	<u>202190959</u>	Published 31.10.2021
	China	08.05.2021	201980073852.4	Published 18.06.2021
	United States of America	12.05.2021	17293446	Published 30.12.2021

TPO No.	125			
Appl. No.	WO2020113199			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020113199">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020113199</a>			
Applicants	INTERNATIONAL AIDS VACCINE INITIATIVE THE SCRIPPS RESEARCH INSTITUTE SCHIEF, William, R. STEICHEN, Jon, M.			
Priority Date	62/774,178 01.12.2018 US			
Details	HIV biologic: Applicant IAVI & Scripps Research Institute, filed an application claiming recombinant HIV env gp120 polypeptide as immunogen for treatment and prophylaxis of HIV. TPO was filed using 7 prior art documents in 4 notes, challenging novelty, and/or inventive step.			
Date of Filing of TPO	01/04/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	European Patent Office	01.07.2021	<u>2019888314</u>	Published 06.10.2021

TPO No.	126			
Appl. No.	WO2020117740			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020117740">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020117740</a>			
Applicants	INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, BURTON, Dennis, R., ANDRABI, Raiees			
Priority Date	62/774,693 03.12.2018 US			
Details	HIV biologic: Applicant IAVI & Scripps Research Institute filed another similar application for isolated variant of HIV env Gp120 polypeptide used as vaccine candidate for HIV. TPO was filed in which 5 prior art documents were used in 4 notes for challenging inventive step.			
Date of Filing of TPO	06/04/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	European Patent Office	05.07.2021	<u>2019892591</u>	Published 13.10.2021

TPO No.	127			
Appl. No.	WO2020121161			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020121161">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020121161</a>			
Applicants	VIIV HEALTHCARE UK (NO.4) LIMITED			
Priority Date	62/777,432 10.12.2018 US 62/874,557 16.07.2019 US			
Details	HIV: Applicant Viivcare Healthcare UK Ltd., filed an application for anhydrous crystalline mesylate salts of lupane derivatives and HIV maturation inhibitor in combination with other anti-HIV drugs. TPO was filed in which 5 prior art documents were used in 5 notes to challenge novelty and, or inventive step.			
Date of Filing of TPO	12/04/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	25.05.2021	17296627	Published 27.01.2022
	Japan	08.06.2021	2021532391	
	European Patent Office	12.07.2021	<u>2019823817</u>	Published 20.10.2021

TPO No.	128			
Appl. No.	WO2020131597			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020131597">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020131597</a>			
Applicants	MERCK SHARP & DOHME CORP. <i>et al.</i>			
Priority Date	62/781,356 18.12.2018 US			
Details	HIV: Applicant Merck, Sharp & Dohme Corp., filed an application claiming pyrimidone derivatives that selectively kill HIV infected cells, having activity as NNRTIs and as selective cytotoxic agents against HIV infected Gag-Pol expressing cells. TPO was filed in which 3 prior art documents were used in 3 notes to challenge inventive step, novelty.			
Date of Filing of TPO	19/04/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	08.06.2021	<u>3122571</u>	Published 25.06.2020
	Israel	08.06.2021	<u>283821</u>	
	United Arab Emirates	14.06.2021	P6000988/2021	
	Nicaragua	14.06.2021	2021-000048 I	Published 09.08.2021
	United States of America	14.06.2021	17413882	Published 03.03.2022
	Costa Rica	15.06.2021	CR2021-000317	Published 14.07.2021
	Peru	15.06.2021	000891-2021	Published 01.09.2021
	Philippines	15.06.2021	12021551408	
	Japan	16.06.2021	2021534709	
	Mexico	17.06.2021	MX/a/2021/007382	Published 12.08.2021
	Thailand	17.06.2021	2101003588	
	Dominican Republic	18.06.2021	DOP2021000129	Published 15.08.2021
	New Zealand	22.06.2021	777465	Published 25.06.2021
	Brazil	29.06.2021	112021011733	
	Republic of Korea	14.07.2021	<u>1020217022074</u>	Published 25.08.2021
	Georgia	16.07.2021	15697/1	
Ukraine	16.07.2021	<u>a202104161</u>	Published 03.11.2021	

	European Patent Office	19.07.2021	<u>2019845846</u>	Published 27.10.2021
	China	18.08.2021	201980092427.X	Published 21.09.2021
	Saudi Arabia	05.02.2022	521422317	
	Eurasian Patent Organization		<u>202191711</u>	Published 31.10.2021

TPO No.	129			
Appl. No.	WO2020131764			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020131764">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020131764</a>			
Applicants	MERCK SHARP & DOHME CORP. <i>et al.</i>			
Priority Date	62/781,204 18.12.2018 US			
Details	HIV biologic: Applicant, Merck, Sharp, & Dohme Corp., filed an application for method for treating HIV by administering antagonist anti-butyrophilin antibody, wherein the antibody activates CD4+T cells and reactivates HIV from latency. TPO was filed in which 3 prior art documents were used in 3 notes to challenge inventive step.			
Date of Filing of TPO	19/04/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	17.06.2021	17415031	Published 03.03.2022
	European Patent Office	19.07.2021	<u>2019901033</u>	Published 27.10.2021

TPO No.	130			
Appl. No.	WO2020150091			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020150091">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020150091</a>			
Applicants	MERCK SHARP & DOHME CORP. <i>et al.</i>			
Priority Date	62/792,455 15.01.2019 US			
Details	HIV: Applicant, Merck, Sharp, & Dohme Corp. , filed an application claiming histone deacetylase inhibitors (HDACi) as latency reversing agents in treatment and prophylaxis of HIV. TPO was filed using 2 prior art documents in 2 notes, challenging novelty, and/or inventive step.			
Date of Filing of TPO	06/05/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	13.07.2021	17422642	Published 24.03.2022
	European Patent Office	16.08.2021	<u>2020741843</u>	Published 24.11.2021

TPO No.	131			
Appl. No.	WO2020146770			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020146770">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020146770</a>			
Applicants	BETH ISRAEL DEACONESS MEDICAL CENTER, INC. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA			
Priority Date	62/791,287 11.01.2019 US			
Details	COVID: Applicant, Beth Israel Deaconess Medical Centre, Inc., & the Regents of the University of California, filed an application claiming use of COX-2 and soluble epoxide hydrolase inhibitor, as dual therapy or co-administered, to treat or prevent cytokine or lipid storm in COVID. The experimental data for this application is in respect to cancer, but, cytokine storms are known in COVID-19, and have been claimed specifically in the application for the treatment of SARS and coronavirus. TPO was filed in which 7 prior art documents were used in 4 notes for challenging novelty, and / or inventive step.			
Date of Filing of TPO	11/05/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	09.07.2021	17421785	Published 24.03.2022

TPO No.	132			
Appl. No.	WO2020150369			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020150369">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020150369</a>			
Applicants	GHOSH, Arun K. et al.			
Priority Date	62/792,668 15.01.2019 US			
Details	HIV: Applicants Ghosh, et al., filed an application for protease inhibitors, its prodrugs, and use against darunavir-resistant HIV strains, and resistant HIV strains. TPO was filed in which 5 prior art documents were used in 4 notes to challenge novelty and, or inventive step.			
Date of Filing of TPO	17/05/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	15.07.2021	17423245	
	European Patent Office	16.08.2021	<u>2020742121</u>	Published 19.01.2022

TPO No.	133			
Appl. No.	WO2020150136			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020150136">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020150136</a>			
Applicants	GILEAD SCIENCES, INC.			
Priority Date	62/792,714 15.01.2019 US			
Details	HCV: Applicant Gilead Sciences Inc., filed an application claiming farsenoid X receptor agonist in combination with ASK1 inhibitor or ACC inhibitor or THR beta agonist to treat NASH, viral hepatitis, liver disorders, and HCV. TPO was filed in which 5 prior art documents were used in 4 notes to challenge novelty, inventive step.			
Date of Filing of TPO	17/05/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Philippines	17.06.2021	12021551483	
	Australia	24.06.2021	<u>2020209564</u>	
	New Zealand	24.06.2021	777524	Published 25.06.2021
	Brazil	29.06.2021	112021011762	
	Israel	04.07.2021	<u>284591</u>	
	Thailand	12.07.2021	2101004123	
	Japan	13.07.2021	2021540517	
	China	14.07.2021	202080009189.4	Published 24.08.2021
	Costa Rica	14.07.2021	CR2021-000385	Published 14.09.2021
	Dominican Republic	14.07.2021	DOP2021000148	Published 31.08.2021
	Mexico	14.07.2021	MX/a/2021/008518	Published 20.09.2021
	Peru	14.07.2021	001167-2021	Published 28.09.2021
	Ukraine	09.08.2021	<u>a202104442</u>	Published 05.10.2021
	Republic of Korea	11.08.2021	<u>1020217025511</u>	Published 23.09.2021
	European Patent Office	16.08.2021	<u>2020708721</u>	Published 24.11.2021
Canada		<u>3124702</u>	Published 21.07.2021	
Eurasian Patent Organization		<u>202191566</u>	Published 30.11.2021	

TPO No.	134			
Appl. No.	WO2020147504			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020147504">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020147504</a>			
Applicants	MERCK SHARP & DOHME CORP. et al.			
Priority Date	62/793,922 18.01.2019 US			
Details	TB: Applicant, Merck, Sharp, & Dohme Corp., filed an application claiming oxazolidinone compounds and their phosphate analogs, alone or in combination with other anti-TB drugs to treat TB. TPO was filed in which 3 prior art documents were used in 3 notes to challenge novelty, and inventive step.			
Date of Filing of TPO	18/05/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	12.07.2021	17422308	Published 17.03.2022
	European Patent Office	18.08.2021	<u>2019909987</u>	Published 01.12.2021

TPO No.	135			
Appl. No.	WO2020154174			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020154174">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020154174</a>			
Applicants	THE J. DAVID GLADSTONE INSTITUTES, et al.			
Priority Date	62/794,850 21.01.2019 US			
Details	HIV: Applicant, J. David Gladstone Institutes, filed an application claiming FOXO1 inhibitors and ER stress inducing agents in combination with HDACi/ protein kinase C activator/ bromodomain inhibitor as latency reversing agents for the treatment and prophylaxis of HIV. TPO was filed in which 7 prior art documents were used in 3 notes to challenge novelty, and/or inventive step.			
Date of Filing of TPO	21/05/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	20.07.2021	17424453	Published 23.06.2022

TPO No.	136			
Appl. No.	WO2020159169			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020159169">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020159169</a>			
Applicants	BIOAPPLICATIONS INC., INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, QURATIS INC.			
Priority Date	10-2019-0010431 28.01.2019 KR			
Details	TB Biologic: Applicants, Bioapplications Inc., Industry-Academic Cooperation Foundation, & Quratis Inc., filed an application for a vaccine for preventing TB comprising of glycosylated Ag85A protein expressed in plant cells. TPO was filed in which 5 prior art documents were used in 3 notes to challenge novelty, and/ or inventive step.			
Date of Filing of TPO	27/05/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Japan	27.07.2021	2021543360	
	China	28.07.2021	202080011317.9	Published 07.09.2021
	United States of America	28.07.2021	17426275	Published 24.03.2022
	European Patent Office	30.08.2021	<u>2020748794</u>	Published 08.12.2021

TPO No.	137			
Appl. No.	WO2020157692			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020157692">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020157692</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Date	62/799,800 01.02.2019 US			
Details	HIV: Applicant, ViiV Healthcare UK (No.5) Ltd., filed an application claiming specific stereoisomer, i.e. atropisomer of HIV capsid inhibitor for use in treatment of HIV in combination with antiretroviral. TPO was filed using 3 prior art documents in 2 notes, challenging novelty, and/or inventive step.			
Date of Filing of TPO	01/06/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	26.07.2021	17425796	Published 07.04.2022
	Japan	30.07.2021	2021544518	
	European Patent Office	01.09.2021	<u>2020704596</u>	Published 08.12.2021

TPO No.	138			
Appl. No.	WO2020165741			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020165741">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020165741</a>			
Applicants	HETERO LABS LIMITED			
Priority Date	201941005217 11.02.2019 IN			
Details	HIV: Applicant, Hetero Labs Ltd., filed an application claiming betulinic acid or triterpene derivatives as HIV maturation inhibitor for use in prevention or treatment of HIV. TPO was filed in which 5 prior art documents were used in 4 notes for challenging novelty, and / or inventive step.			
Date of Filing of TPO	11/06/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	10.08.2021	<u>3129743</u>	Published 12.09.2021
	Israel	10.08.2021	<u>285487</u>	
	Japan	10.08.2021	2021546849	
	Mexico	10.08.2021	MX/a/2021/009584	Published 14.10.2021
	Thailand	10.08.2021	2101004761	
	United States of America	11.08.2021	17430130	Published 09.06.2022
	Brazil	17.08.2021	112021015762	
	Eurasian Patent Organization	27.08.2021	<u>202192111</u>	Published 31.01.2022
	Republic of Korea	06.09.2021	<u>1020217028594</u>	Published 25.10.2021
	Australia	08.09.2021	<u>2020222299</u>	
	New Zealand	08.09.2021	779851	Published 24.09.2021
	European Patent Office	13.09.2021	<u>2020720927</u>	Published 22.12.2021
	China	08.10.2021	202080027246.1	Published 30.11.2021

TPO No.	139			
Appl. No.	WO2020167919			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020167919">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020167919</a>			
Applicants	REGENERON PHARMACEUTICALS, INC.			
Priority Date	62/804,358 12.02.2019 US			
Details	COVID: Biologic application: Applicants Regeneron Pharmaceuticals, Inc., filed an application for bispecific antigen binding molecule, wherein one domain binds to the target, like CoV, antigen and the other domain binds to a complement component, C1q component, and its pharmaceutical compositions for treatment of viral diseases, etc.. TPO was filed in which 12 prior art documents were used in 6 notes to challenge novelty and, or inventive step.			
Date of Filing of TPO	14/06/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	08.07.2021	<u>2020223205</u>	
	Canada	22.07.2021	<u>3127696</u>	Published 22.08.2021
	Japan	04.08.2021	2021545677	
	China	05.08.2021	202080012874.2	Published 17.09.2021
	Israel	05.08.2021	<u>285404</u>	
	Mexico	09.08.2021	MX/a/2021/009533	Published 13.12.2021
	United States of America	11.08.2021	17430117	Published 19.05.2022
	Republic of Korea	03.09.2021	<u>1020217028365</u>	Published 20.10.2021
	European Patent Office	13.09.2021	<u>2020710016</u>	Published 22.12.2021
	Russian Federation	13.09.2021	2021126679	

TPO No.	140			
Appl. No.	WO2020169705			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020169705">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020169705</a>			
Applicants	BIOMEDREX AB			
Priority Date	1950215-2 20.02.2019 SE 1950216-0 20.02.2019 SE 1950217-8 20.02.2019 SE 1950218-6 20.02.2019 SE			
Details	HIV: Biologic application: Applicant Biomedrex AB., filed an application claiming a therapy for HIV using CRISPR Cas system, where the protein is selected from one of Cpf1(Cas12a) and Cas13 and the RNA guide strand. TPO was filed in which 8 prior art documents were used in 6 notes to challenge inventive step.			
Date of Filing of TPO	21/06/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	18.08.2021	17431945	Published 21.04.2022

TPO No.	141			
Appl. No.	WO2020178767			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020178767">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020178767</a>			
Applicants	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED VIIV HEALTHCARE COMPANY			
Priority Date	62/814,316 06.03.2019 US			
Details	HIV: Applicant, GlaxoSmithKline Intellectual Property Development Ltd. & ViiV Healthcare Co., filed an application claiming long chain pro drugs and analogues of NRTIs, especially EFdA/MK-8591/ Islatravir, a known nucleoside analogue, as treatment for HIV, also in combination with other anti-HIV drugs. TPO was filed using 4 prior art documents in 3 notes, challenging novelty, and/or inventive step.			
Date of Filing of TPO	06/07/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	New Zealand	25.08.2021	779345	Published 27.08.2021
	Dominican Republic	26.08.2021	DOP2021000180	Published 31.01.2022
	Israel	26.08.2021	<u>285894</u>	
	Australia	30.08.2021	<u>2020231934</u>	
	Costa Rica	02.09.2021	CR2021-000460	Published 03.02.2022
	Japan	03.09.2021	2021552772	
	Mexico	03.09.2021	MX/a/2021/010700	Published 17.11.2021
	Thailand	03.09.2021	2101005255	
	Peru	06.09.2021	001461-2021	Published 04.11.2021
	Brazil	14.09.2021	112021017604	
	Eurasian Patent Organization	05.10.2021	<u>202192433</u>	Published 31.12.2021
	Ukraine	05.10.2021	<u>a202105608</u>	Published 02.02.2022
	European Patent Office	06.10.2021	<u>2020712038</u>	Published 12.01.2022
	Russian Federation	06.10.2021	2021128918	
	China	21.10.2021	202080030422.7	Published 17.12.2021
	Canada		<u>3132112</u>	Published 30.09.2021
Republic of Korea		<u>1020217031465</u>	Published 16.11.2021	

TPO No.	142			
Appl. No.	WO2020190827			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020190827">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020190827</a>			
Applicants	MERCK SHARP & DOHME CORP. et al.			
Priority Date	62/821,505 21.03.2019 US			
Details	HIV: Applicant, Merck Sharp & Dohme Corporation, filed an application claiming macrocyclic HDAC inhibitors for treatment and prophylaxis of HIV. TPO was filed in which 5 prior art documents were used in 3 notes for challenging inventive step.			
Date of Filing of TPO	21/07/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	13.09.2021	17438479	Published 12.05.2022
	European Patent Office	21.10.2021	<u>2020772525</u>	Published 26.01.2022

TPO No.	143			
Appl. No.	WO2020197991			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020197991">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020197991</a>			
Applicants	GILEAD SCIENCES, INC.			
Priority Date	62/822,703 22.03.2019 US 62/948,697 16.12.2019 US			
Details	HIV: Applicants Gilead Sciences Inc., filed an application for bridged tricyclic carbamoylpyridone compounds as anti-HIV agents. TPO was filed in which 2 prior art documents were used in 2 notes to challenge inventive step.			
Date of Filing of TPO	22/07/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	01.09.2021	<u>3128961</u>	Published 12.09.2021
	Israel	13.09.2021	<u>286328</u>	
	Eurasian Patent Organization	14.09.2021	<u>202192268</u>	Published 31.01.2022
	Mexico	20.09.2021	MX/a/2021/011394	Published 17.11.2021
	Costa Rica	21.09.2021	CR2021-000486	Published 07.12.2021
	Dominican Republic	21.09.2021	DOP2021000195	Published 31.10.2021
	Japan	21.09.2021	2021556755	
	Peru	21.09.2021	001560-2021	Published 26.10.2021
	Thailand	21.09.2021	2101005730	
	Brazil	28.09.2021	112021018827	
	European Patent Office	14.10.2021	<u>2020719849</u>	Published 19.01.2022 Granted 22.06.2022
	Ukraine	18.10.2021	<u>a202105473</u>	Published 16.02.2022
	Australia	21.10.2021	<u>2020245350</u>	
	New Zealand	21.10.2021	781550	Published 29.10.2021
	Republic of Korea	22.10.2021	<u>1020217034340</u>	Published 25.11.2021
	China	05.11.2021	202080034051.X	Published 31.12.2021

TPO No.	144			
Appl. No.	WO2020198337			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020198337">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020198337</a>			
Applicants	OHIO STATE INNOVATION FOUNDATION			
Priority Date	62/823,215 25.03.2019 US			
Details	COVID: Biologic application: Applicant Ohio State Innovation Foundation, filed an application claiming engineered mRNA sequences as a treatment for COVID. TPO was filed in which 3 prior art documents were used in 2 notes to challenge inventive step.			
Date of Filing of TPO	26/07/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	23.09.2021	17442471	Published 26.05.2022
	Japan	24.09.2021	2021557346	
	Australia	21.10.2021	<u>2020245537</u>	
	European Patent Office	25.10.2021	<u>2020778510</u>	Published 09.02.2022
	China	24.11.2021	202080038786.X	Published 18.03.2022
	Canada		<u>3134944</u>	Published 26.10.2021

TPO No.	145			
Appl. No.	WO2020206232			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020206232">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020206232</a>			
Applicants	VANDERBILT UNIVERSITY			
Priority Date	62/829,526 04.04.2019 US 62/971,477 07.02.2020 US			
Details	HIV & HCV: Biologic: Applicant, Vanderbilt University filed an application claiming recombinant antibody binding to at least one HIV antigen or HCV antigen for treatment of co-infection of HIV & HCV. TPO was filed using 6 prior art documents in 4 notes, challenging novelty, and/or inventive step.			
Date of Filing of TPO	04/08/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	01.10.2021	17600893	Published 16.06.2022
	European Patent Office	04.11.2021	<u>2020785367</u>	Published 09.02.2022

TPO No.	146			
Appl. No.	WO2020214961			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020214961">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020214961</a>			
Applicants	CODIAK BIOSCIENCES, INC.			
Priority Date	62/835,427 17.04.2019 US 62/840,330 29.04.2019 US 62/851,567 22.05.2019 US			
Details	TB: Biologic: Applicant, Codiak Biosciences, Inc., filed an application claiming a method of inducing an increased immune response in people with TB by using engineered exosome comprising of IL-12 and an M.Tb antigen - ESAT6 or TB10.4, and scaffolds for the exosomes. TPO was filed in which 6 prior art documents were used in 4 notes for challenging novelty and / or inventive step or inventive step only.			
Date of Filing of TPO	17/08/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	14.10.2021	17594401	Published 14.07.2022

TPO No.	147
Appl. No.	WO2020219808
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020219808">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020219808</a>
Applicants	BETA PHARMA, INC.
Priority Date	62/838,925 25.04.2019 US
Details	HCV: Applicant, Beta Pharma, filed an application claiming uses and methods for preparation of dicarbamate compounds as inhibitors of NS5A for treating HCV and related diseases. TPO was filed in which 3 prior art documents were used in 3 notes to challenge novelty and / or inventive step.
Date of Filing of TPO	25/08/2021
National Phase	No National Phase Data

TPO No.	148			
Appl. No.	WO2020220018			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020220018">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020220018</a>			
Applicants	HOWARD UNIVERSITY GEORGETOWN UNIVERSITY ULLAH, Heyamet DAKSHANAMURTHY, Sivanesan			
Priority Date	62/839,402 26.04.2019 US			
Details	COVID: Applicant Howard University, filed an application claiming combinatorial method of treating herpes simplex virus and COVID by inhibiting the replication of IRES-utilizing virus in cells. TPO was filed in which 6 prior art documents were used in 4 notes to challenge novelty and/or inventive step. An additional note was also submitted challenging the priority of the claims for COVID.			
Date of Filing of TPO	26/08/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	26.10.2021	17606542	Published 07.07.2022
	European Patent Office	26.11.2021	<u>2020796172</u>	Published 02.03.2022

TPO No.	149			
Appl. No.	WO2020231855			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020231855">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020231855</a>			
Applicants	NANT HOLDINGS IP, LLC, NANTBIO, INC., ALTOR BIOSCIENCE CORPORATION			
Priority Date	62/846,186 10.05.2019 US 62/904,019 23.09.2019 US 62/984,085 02.03.2020 US 62/985,074 04.03.2020 US			
Details	HIV, HCV & COVID: Applicant, Nant Holdings, filed an application for IL-15 agonist, particularly Nogapendekin Alfa-Inbakicept (NAI) claiming methods of prevention and treatment of viral infections by administering IL-15 agonist at a dose that increases the proliferative capacity of NK cells or T-cells. Though application is for HIV, it has been disclaimed in the first claim. COVID claims have been added as an amendment. The NAI appears to have got emergency use approval for COVID in the USA. TPO was filed using 4 prior art documents in 3 notes, challenging novelty, and/or inventive step.			
Date of Filing of TPO	10/09/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	03.11.2021	17594940	Published 14.07.2022

TPO No.	150
Appl. No.	WO2020234636
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020234636">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020234636</a>
Applicants	CADILA HEALTHCARE LIMITED
Priority Date	201921019532 17.05.2019 IN
Details	TB: Applicant, Cadila Healthcare, filed an application claiming oxazolididone compounds and their analogues, useful for treating TB, either alone or in combination. TPO was filed in which 3 prior art documents were used in 2 notes for challenging inventive step.
Date of Filing of TPO	17/09/2021
National Phase	No National Phase Data

TPO No.	151			
Appl. No.	WO2020237044			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020237044">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020237044</a>			
Applicants	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION			
Priority Date	62/850,942 21.05.2019 US			
Details	TB: Biologic: Applicant, University of Pittsburg, of the Commonwealth System of Higher Education, filed an application claiming two or more mycobacteriophages for treatment of TB. TPO was filed in which 6 prior art documents were used in 4 notes to challenge inventive step.			
Date of Filing of TPO	21/09/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	19.11.2021	17612926	Published 28.07.2022

TPO No.	152
Appl. No.	WO2020237052
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020237052">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020237052</a>
Applicants	JANSSEN VACCINES & PREVENTION B.V. GILEAD SCIENCES, INC.
Priority Date	62/851,258 22.05.2019 US
Details	HIV: Biologic: Applicant, Janssen Vaccine and Prevention B.V., and Gilead Sciences filed an application claiming method of administering a vaccine with AD26 and MVA vectors presenting HIV antigens and a TLR7 agonist vasatolimod (GS-9620) and gp140 vaccine for the treatment of a human infected with HIV and undergoing ART. TPO was filed in which 1 prior art document was used in 1 note to challenge novelty and/or inventive step.
Date of Filing of TPO	22/09/2021
National Phase	No National Phase Data

TPO No.	153			
Appl. No.	WO2020237027			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020237027">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020237027</a>			
Applicants	GILEAD SCIENCES, INC. AELIX THERAPEUTICS S.L.			
Priority Date	62/851,363 22.05.2019 US			
Details	HIV: Biologic: Applicant, Gilead Sciences, Inc. and Aelix Therapeutics S.L., filed an application claiming method of treating or preventing an HIV infection in a human (including those who are virologically suppressed due to ART or at risk of developing HIV infection) comprising GS-9620, a TLR7 agonist vesatolimod, and virus comprising a nucleic acid encoding HIV immunogenic polypeptides. TPO was filed in which 3 prior art documents were used in 1 note to target inventive step.			
Date of Filing of TPO	22/09/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Canada	29.10.2021	<u>3135698</u>	Published 08.12.2021
	United States of America	09.11.2021	17610040	Published 14.07.2022
	China	19.11.2021	202080037405.6	Published 11.01.2022
	Japan	19.11.2021	2021569363	
	Australia	16.12.2021	<u>2020280040</u>	
	Republic of Korea	20.12.2021	<u>1020217041663</u>	Published 28.01.2022
	European Patent Office	22.12.2021	<u>2020731741</u>	Published 30.03.2022

TPO No.	154			
Appl. No.	WO2020247837			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020247837">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020247837</a>			
Applicants	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA			
Priority Date	62/858,506 07.06.2019 US			
Details	HIV: Biologic: Applicant, Trustees of the University of Pennsylvania, filed an application claiming an immune cell which is transformed containing a vector (preferably lentiviral) containing nucleic acid with polynucleotide sequences, encoding a dual chimeric antigen receptor (CART). TPO was filed using 2 prior art documents in 1 note, challenging inventive step.			
Date of Filing of TPO	07/10/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	04.12.2021	<u>2020286471</u>	
	Japan	06.12.2021	2021572436	
	European Patent Office	07.01.2022	<u>2020818563</u>	Published 13.04.2022

TPO No.	155			
Appl. No.	WO2020252305			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020252305">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2020252305</a>			
Applicants	THE J. DAVID GLADSTONE INSTITUTES, et al.			
Priority Date	62/861,723 14.06.2019 US			
Details	HIV: Biologic: Applicant, J. David Gladstone Institutes, filed an application claiming constructs of therapeutic interfering particles (TIPs) with cis-acting elements, and one or more alterations in an HIV nucleotide sequence that renders the Pol, Tat, Vpr, Nef, and Vif non-functional so that the construct is incapable of replicating the virus on its own. TPO was filed in which 1 prior art document was used in 1 note for challenging novelty and inventive step.			
Date of Filing of TPO	14/10/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Japan	14.12.2021	2021574334	
	Thailand	14.12.2021	2101007788	
	United States of America	14.12.2021	17619063	
	European Patent Office	14.01.2022	2020735753	Published 20.04.2022

TPO No.	156			
Appl. No.	WO2020254985			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020254985">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020254985</a>			
Applicants	VIIV HEALTHCARE UK (NO.5) LIMITED			
Priority Data	62/863,406 19.06.2019 US			
Details	HIV: Applicant, ViiV Healthcare, filed an application claiming pharmaceutical compositions of HIV capsid inhibitors, mainly Pyrido[2,3-d]pyrimidine derivatives, for treating HIV, either alone or in combination. TPO was filed in which 5 prior art documents were used in 3 notes that challenged novelty, and also inventive step.			
Date of filing TPO	19/10/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	12.02.2021	17268107	Published 21.10.2021
	Dominican Republic	06.12.2021	DOP2021000253	Published 28.02.2022
	Singapore	06.12.2021	11202113548Q	
	Israel	07.12.2021	<u>288750</u>	
	New Zealand	08.12.2021	783111	Published 24.12.2021
	Australia	16.12.2021	<u>2020295793</u>	
	Peru	16.12.2021	002114-2021	Published 07.04.2022
	Costa Rica	17.12.2021	CR2021-000664	Published 21.01.2022
	Japan	17.12.2021	2021575482	
	Mexico	17.12.2021	MX/a/2021/016149	Published 15.06.2022
	Thailand	17.12.2021	2101007875	
	Brazil	28.12.2021	112021025655	

	Republic of Korea	14.01.2022	<a href="#">1020227001501</a>	Published 03.03.2022
	Eurasian Patent Organization	18.01.2022	<a href="#">202290093</a>	Published 31.05.2022
	China	19.01.2022	202080052305.0	Published 25.03.2022
	European Patent Office	19.01.2022	<a href="#">2020743783</a>	Published 27.04.2022
	Russian Federation	19.01.2022	2022101023	
	Canada		<a href="#">3143136</a>	Published 09.01.2022

TPO No.	157			
Appl. No.	WO2021000684			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021000684">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021000684</a>			
Applicants	MERCK SHARP & DOHME CORP. et al			
Priority Date	PCT/CN2019/094601 03.07.2019 CN			
Details	TB: Applicant, Merck, Sharp & Dohme Corp., filed an application claiming dihydroisoxazoles compounds & compositions, for the treatment of TB. TPO was filed using 5 prior art documents in 2 notes, challenging novelty, and/or inventive step, inventive step only.			
Date of Filing of TPO	03/11/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	15.12.2021	17619338	Published 28.07.2022
	Mexico	16.12.2021	MX/a/2021/015841	Published 08.03.2022
	Australia	21.12.2021	<u>2020300400</u>	
	Israel	23.12.2021	<u>289336</u>	
	Japan	24.12.2021	2021576988	
	Thailand	28.12.2021	2101008191	
	Nicaragua	29.12.2021	2021-000125 I	
	Peru	29.12.2021	002266-2021	Published 30.05.2022
	Dominican Republic	30.12.2021	DOP2021000279	Published 15.02.2022
	Singapore	30.12.2021	11202114569U	
	United Arab Emirates	03.01.2022	P6000007/2022	
	Costa Rica	03.01.2022	CR2022-000003	Published 08.02.2022
	Brazil	11.01.2022	112021026762	
	New Zealand	12.01.2022	784216	Published 28.01.2022
	Eurasian Patent Organization	02.02.2022	<u>202290215</u>	Published 31.03.2022
	Georgia	02.02.2022	15872/1	
	Ukraine	02.02.2022	<u>a202200425</u>	Published 02.03.2022
	European Patent Office	03.02.2022	<u>2020834302</u>	Published 18.05.2022
	China	03.03.2022	202080061811.6	Published 12.04.2022

	Saudi Arabia	19.03.2022	521431285	
	Canada		<u>3145555</u>	Published 26.01.2022
	Republic of Korea		<u>1020227002948</u>	Published 08.03.2022

TPO No.	158			
Appl. No.	WO2021015818			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021015818">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021015818</a>			
Applicants	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES			
Priority Date	62/876,539 19.07.2019 US			
Details	HIV: Applicant, United States of America, DHHS, filed an application claiming a combination of tenofovir, emtricitabine, elvitegravir & cobicistat, to be taken once only as pre-exposure prophylaxis. TPO was filed in which 6 prior art documents were used in 3 notes for challenging inventive step, novelty and/or inventive step.			
Date of Filing of TPO	19/11/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	31.12.2021	<u>2020318808</u>	
	Canada	06.01.2022	<u>3146263</u>	Published 03.02.2022
	United States of America	18.01.2022	17628170	Published 25.08.2022
	European Patent Office	21.02.2022	<u>2020708779</u>	Published 25.05.2022

TPO No.	159			
Appl. No.	WO2021021603			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021021603">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021021603</a>			
Applicants	THE SCRIPPS RESEARCH INSTITUTE			
Priority Date	62/879,100 26.07.2019 US			
Details	HCV: Applicant, Scripps Research Institute, filed an application claiming modified engineered HCV E2 ectodomain polypeptide, with truncation in the V2 region, and deletion in the beta sandwich loop connecting beta sheets 6 & 7 of the beta sandwich domain for use as vaccines for HCV. TPO was filed in which 6 prior art documents were used in 3 notes that challenged inventive step, including a Px document that challenged the novelty &/or inventive step.			
Date of Filing of TPO	26/11/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Singapore	24.01.2022	11202200689X	
	Australia	15.02.2022	<u>2020323462</u>	
	New Zealand	15.02.2022	785133	Published 25.02.2022
	Eurasian Patent Organization	16.02.2022	<u>202290350</u>	Published 30.06.2022
	European Patent Office	28.02.2022	<u>2020846134</u>	Published 01.06.2022
	China	21.03.2022	202080066211.9	Published 14.06.2022
	Canada		<u>3148840</u>	Published 22.02.2022

TPO No.	160			
Appl. No.	WO2021021717			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021021717">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021021717</a>			
Applicants	BRII BIOSCIENCES, INC.			
Priority Date	62/879,414 27.07.2019 US			
Details	HIV: Applicant, Brie Biosciences filed an application claiming adenosine derivatives/medoximil prodrugs of EFdA for the treatment of HIV. TPO was filed with 4 prior art document in 3 notes that challenged inventive step, and novelty &/or inventive step.			
Date of Filing of TPO	29/11/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Australia	06.01.2022	<u>2020320876</u>	
	Canada	07.01.2022	<u>3146679</u>	Published 04.02.2022
	Singapore	07.01.2022	11202200159S	
	New Zealand	08.01.2022	784129	Published 28.01.2022
	Mexico	13.01.2022	MX/a/2022/000563	Published 12.07.2022
	Israel	17.01.2022	<u>289925</u>	
	Brazil	25.01.2022	112022000965	
	Japan	26.01.2022	2022505447	
	European Patent Office	28.02.2022	<u>2020848596</u>	Published 01.06.2022
	Russian Federation	28.02.2022	2022104985	
	China	21.03.2022	202080066036.3	Published 13.05.2022
	United States of America		17630403	Published 15.09.2022

TPO No.	161			
Appl. No.	WO2021024114			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021024114">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021024114</a>			
Applicants	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED VIIV HEALTHCARE COMPANY			
Priority Date	62/884,191 08.08.2019 US			
Details	HIV: Applicant, Glaxosmithkline Intellectual Property, Viiv Healthcare Co., filed an application claiming nucleoside analogues of formula I for the treatment & prevention of HIV. It claimed structures with prodrug modifications to EFdA, including triglyceride prodrugs. TPO was filed using 5 prior art documents in 3 notes, challenging novelty, and/or inventive step, inventive step only.			
Date of Filing of TPO	08/12/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	27.01.2022	17630608	Published 18.08.2022
	Japan	07.02.2022	2022507749	
	European Patent Office	09.03.2022	<u>2020753440</u>	Published 15.06.2022

TPO No.	162			
Appl. No.	WO2021034804			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021034804">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021034804</a>			
Applicants	GILEAD SCIENCES, INC.			
Priority Date	62/888,959 19.08.2019 US			
Details	HIV: Applicant, Gilead, filed an application claiming long acting formulations of tenofovir alfenamide, and its various salts like hemipamoate, sebacate, napsylate, orotate, vanillate, bis-xinafoate salts, and crystalline forms, & biodegradable polymer – PLGA as anti-HIV agents. TPO was filed in which 5 prior art documents were used in 3 notes for challenging inventive step.			
Date of Filing of TPO	20/12/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	European Patent Office	21.03.2022	<u>2020765138</u>	Published 29.06.2022
	United States of America		17636511	Published 22.09.2022

TPO No.	163			
Appl. No.	WO2021035214			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021035214">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021035214</a>			
Applicants	EMORY UNIVERSITY			
Priority Date	62/890,452 22.08.2019 US 62/890,684 23.08.2019 US			
Details	HIV: Applicant, Emory University, filed an application claiming lipid esters of nucleoside phosphonates, including tenofovir, that resist enzyme mediated omega oxidation. TPO was filed in which 6 prior art documents were used in 3 notes that challenged novelty &/or inventive step.			
Date of Filing of TPO	22/12/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	Israel	20.02.2022	<u>290739</u>	
	Japan	21.02.2022	2022511257	
	United States of America	22.02.2022	17637365	Published 22.09.2022
	Australia	26.02.2022	<u>2020334152</u>	
	Republic of Korea	21.03.2022	<u>1020227009375</u>	Published 20.06.2022
	European Patent Office	22.03.2022	<u>2020855810</u>	Published 29.06.2022
	China	29.03.2022	202080068605.8	Published 13.05.2022
	Canada		<u>3152013</u>	Published 23.03.2022

TPO No.	164			
Appl. No.	WO2021038509			
Link to Appl.	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021038509">https://patentscope.wipo.int/search/en/detail.jsf?docId= WO2021038509</a>			
Applicants	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED VIIV HEALTHCARE COMPANY			
Priority Date	62/892,577 28.08.2019 US			
Details	HIV: Applicant, Glaxosmithkline Intellectual Property & Viiv Healthcare Co., filed an application claiming nucleoside analogues of formula I for the treatment & prevention of HIV. It claimed structures with prodrug modifications to EFdA. TPO was filed using 5 prior art documents in 3 notes, challenging novelty, and/or inventive step, inventive step only. This Application is slightly broader than applications at TPO # 161.			
Date of Filing of TPO	28/12/2021			
National Phase	<b>Office</b>	<b>Entry Date</b>	<b>National Number</b>	<b>National Status</b>
	United States of America	16.02.2022	17635776	Published 22.09.2022
	Japan	25.02.2022	2022513413	Non Entry 06.07.2022
	European Patent Office	28.03.2022	<u>2020768101</u>	Published 06.07.2022